Dr. Mayer discusses the mechanism of action of SERDs in ER-positive breast cancer, highlighted data from the AMEERA-1 trial with amcenestrant and palbociclib, and details future research efforts with SERDs.
Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Sanofi, we had the pleasure of speaking with Ingrid A. Mayer, MD, MSCI, co-leader of the Breast Cancer Research Program, a professor of medicine (Hematology/Oncology), the Ingram Professor of Cancer Research, and chair of the Data and Safety Monitoring Committee at Vanderbilt-Ingram Cancer Center, to discuss the development of selective estrogen receptor downregulators (SERDs) in estrogen receptor (ER)–positive breast cancer.
Currently, fulvestrant (Faslodex) is the only SERD approved for use in women with ER-positive, HER2-negative advanced breast cancer. However, other SERDs, such as amcenestrant, are in development.
Amcenestrant is an investigational, optimized oral SERD that is under study in the phase 1/2 AMEERA-1 trial (NCT03284957). Initial findings from the trial, which were presented during the 2021 ASCO Annual Meeting, demonstrated that amcenestrant in combination with the CDK4/6 inhibitor palbociclib (Ibrance) led to an objective response rate of 34.3% and a clinical benefit rate of 74.3% in patients with endocrine-resistant, ER-positive, HER2-negative advanced breast cancer. Moreover, the combination exhibited a favorable safety profile.
In our exclusive interview, Mayer discussed the mechanism of action of SERDs in ER-positive breast cancer, highlighted data from the AMEERA-1 trial with amcenestrant and palbociclib, and detailed the design of the ongoing AMEERA-5 trial (NCT04478266).